Product/Composition:- | Clarithromycin Suspension |
---|---|
Strength:- | 125 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL |
Form:- | Suspension |
Reference Brands:- | Biaxin (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Clarithromycin suspension inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing translocation. It is effective against respiratory and Helicobacter pylori infections. Benefits include rapid, broad-spectrum activity, good tissue penetration, and convenient oral suspension for pediatric and adult use.
Clarithromycin suspension is approved in the EU and US for pediatric respiratory and Helicobacter pylori infections. In the EU, brands like Klacid are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality standards. In the US, FDA approval relies on extensive clinical data; generics are available. Both regions require detailed dossiers, clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety. For expert guidance on regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for clarithromycin suspension, ensuring adherence to European and US standards for safe and effective pediatric and adult antimicrobial therapy.